-
Je něco špatně v tomto záznamu ?
Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma
H. Mocikova, R. Pytlik, J. Markova, K. Steinerova, Z. Kral, D. Belada, M. Trnkova, M. Trneny, V. Koza, J. Mayer, P. Zak, T. Kozak,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- autologní transplantace MeSH
- dospělí MeSH
- Hodgkinova nemoc mortalita terapie MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- pozitronová emisní tomografie MeSH
- prognóza MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- staging nádorů MeSH
- transplantace hematopoetických kmenových buněk MeSH
- výsledek terapie MeSH
- záchranná terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
This retrospective study evaluated the secondary clinical risk score at relapse, the prognostic significance of pre-transplant positron emission tomography (PET), and complete remission (CR) assessed by computed tomography (CT) after salvage chemotherapy before autologous stem cell transplant (ASCT) in 76 patients with relapsed/refractory Hodgkin lymphoma (HL). Median follow-up after ASCT was 23 months. Overall 11/20 PET-positive and 14/56 PET-negative patients relapsed after ASCT. In univariate analysis, only PET negativity before ASCT was significantly associated with better 2-year progression-free survival (PFS) (72.7 ± 6.3% vs. 36.1 ± 11.6%, p = 0.01) and 2-year overall survival (OS) (90.3 ± 4.1% vs. 61.4 ± 11.6%, p = 0.009). Other factors were not significant. In multivariate analysis, none of the evaluated factors were significant for PFS and OS. However, positive pre-transplant PET identified a population with worse PFS and OS at least in univariate analysis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12028222
- 003
- CZ-PrNML
- 005
- 20121126195933.0
- 007
- ta
- 008
- 120817e20110623enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.3109/10428194.2011.573889 $2 doi
- 035 __
- $a (PubMed)21699377
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Móciková, Heidi, $d 1964- $7 mzk2009517509 $u Department of Clinical Hematology, Charles University Hospital Kralovske Vinohrady, Prague, Czech Republic. heidi.mocikova@seznam.cz
- 245 10
- $a Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma / $c H. Mocikova, R. Pytlik, J. Markova, K. Steinerova, Z. Kral, D. Belada, M. Trnkova, M. Trneny, V. Koza, J. Mayer, P. Zak, T. Kozak,
- 520 9_
- $a This retrospective study evaluated the secondary clinical risk score at relapse, the prognostic significance of pre-transplant positron emission tomography (PET), and complete remission (CR) assessed by computed tomography (CT) after salvage chemotherapy before autologous stem cell transplant (ASCT) in 76 patients with relapsed/refractory Hodgkin lymphoma (HL). Median follow-up after ASCT was 23 months. Overall 11/20 PET-positive and 14/56 PET-negative patients relapsed after ASCT. In univariate analysis, only PET negativity before ASCT was significantly associated with better 2-year progression-free survival (PFS) (72.7 ± 6.3% vs. 36.1 ± 11.6%, p = 0.01) and 2-year overall survival (OS) (90.3 ± 4.1% vs. 61.4 ± 11.6%, p = 0.009). Other factors were not significant. In multivariate analysis, none of the evaluated factors were significant for PFS and OS. However, positive pre-transplant PET identified a population with worse PFS and OS at least in univariate analysis.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a Hodgkinova nemoc $x mortalita $x radioizotopová diagnostika $x terapie $7 D006689
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a záchranná terapie $7 D016879
- 650 _2
- $a autologní transplantace $7 D014182
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pytlík, Robert, $d 1967- $7 xx0061345
- 700 1_
- $a Marková, Jana $7 xx0143313
- 700 1_
- $a Steinerová, Kateřina $7 xx0084093
- 700 1_
- $a Král, Zdeněk, $d 1964- $7 nlk20000083648
- 700 1_
- $a Belada, David, $d 1972- $7 mzk2006322730
- 700 1_
- $a Trnkova, Marie
- 700 1_
- $a Trněný, Marek, $d 1960- $7 nlk20000083659
- 700 1_
- $a Koza, Vladimír, $d 1954-2012 $7 nlk19990073416
- 700 1_
- $a Mayer, Jiří, $d 1960- $7 nlk20000083651
- 700 1_
- $a Žák, Pavel, $d 1966- $7 mzk2006354145
- 700 1_
- $a Kozák, Tomáš
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 52, č. 9 (20110623), s. 1668-74
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21699377 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121126200021 $b ABA008
- 999 __
- $a ok $b bmc $g 950264 $s 785568
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 52 $c 9 $d 1668-74 $e 20110623 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20120817/11/04
